Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | S095029 |
Trade Name | |
Synonyms | S-095029|S 095029|Sym 025|Sym-025|Sym025 |
Drug Descriptions |
S095029 is a monoclonal antibody that targets natural killer (NK) and T-lymphocyte cell checkpoint inhibitor killer cell lectin-like receptor subfamily C member 1 (NKG2A), which may result in an antitumor immune response mediated by NK cells and cytotoxic T-lymphocytes (NCI Drug Dictionary). |
DrugClasses | NKG2A Antibody 3 |
CAS Registry Number | NA |
NCIT ID | C185890 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Cemiplimab + S095029 | Cemiplimab S095029 | 0 | 1 |
Futuximab + S095029 + Sym021 | Futuximab S095029 Sym021 | 0 | 1 |
Modotuximab + S095029 + Sym021 | Modotuximab S095029 Sym021 | 0 | 1 |
Pembrolizumab + S095029 | Pembrolizumab S095029 | 0 | 1 |
S095029 | S095029 | 0 | 1 |
S095029 + Sym021 | S095029 Sym021 | 0 | 1 |